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ABSTRACT
Objective: Type 2 diabetes mellitus is a major public health problem. Diabetic neuropathy is one of the major diabetes microvascular complications. 
The previous study suggests that Vitamin D deficiency plays an important role in the development and progression of diabetes and the data in 
Indonesia are very limited. This study aims to measure the prevalence of Vitamin D deficiency and its determinant factors in patients with painful 
diabetic neuropathy (PDN).
Methods: This study is a cross-sectional study. The data were obtained from 53 subjects with diabetic peripheral neuropathy. A pre-designed 
questionnaire was used to collect data on the patient’s age, gender, duration of diabetes, comorbidities, any diabetic complications, and current 
treatment for diabetes mellitus. The Vitamin D levels were measured by a standardized method in the Prodia Research Laboratory.
Results: Study findings showed that from 53 study subjects, most of them were female (79.2%). The mean age of subjects was 57.83±8.79 years. 
We found a high prevalence of low Vitamin D levels in the Indonesian population as many as 98.11% and only 1.9% has sufficiency Vitamin D levels. 
Gender (p=0.028), hypertension (p=0.027), and controlled complications (p=0.005) were significantly associated with Vitamin D levels.
Conclusion: All patients with PDN in this study had a high prevalence of Vitamin D deficiency. This high prevalence of Vitamin D deficiency also has 
been reported worldwide. Physician should be aware and continue to treat patients with Vitamin D deficiency.
Keywords: Diabetes mellitus, Vitamin D deficiency, Low Vitamin D levels, Painful diabetic neuropathy.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a major public health problem, 
accounting for significant premature mortality and morbidity [1]. 
The data from the National Health Survey in Indonesia showed 
that the prevalence of diabetes increases by 2% among >15-year-
old population [2]. Treatment options for type 2 diabetes have 
dramatically improved, but the rising burden calls for more 
insights into the prevention and management of the disease [1]. 
Diabetic neuropathy is one of the major diabetes microvascular 
complications [3]. The pathogenesis of diabetic peripheral 
neuropathy is a multifactorial process and multiple hypotheses 
have been postulated. Previous pre-clinical research concludes that 
abnormal expression of sodium and calcium channels, metabolic and 
autoimmune disorders which lead to glial cell activation contributes 
to the pathogenesis [4].
Vitamin D receptors are present in the β-cells of the pancreas and 
Vitamin D has been linked to insulin secretion regulation [5]. The 
previous review suggests that Vitamin D levels may have an inverse 
relationship with glycated hemoglobin and low levels of Vitamin D 
show a correlation to increased incidence of type 2 diabetes [6]. 
The previous study also suggests that Vitamin D deficiency plays an 
important role in the development and progression of diabetes, while 
high plasma Vitamin D is related to lower risk of developing diabetes 
in high-risk patients. Vitamin D deficiency is involved in central 
pathogenetic mechanisms of diabetes; it affects insulin sensitivity and 
β-cell function [5,6]. The previous epidemiological studies showed 
that Vitamin D deficiency is common in diabetes. A study conducted in 
Saudi Arabia reported a prevalence of 59.8% of Vitamin D deficiency 
and 38.6% insufficiency [7]. In India, 32.1% and 34.6% of type 2 
diabetics had Vitamin D deficiency and insufficiency, respectively [8]. 
Another recent study in 151 subjects with diabetes found that Vitamin 
D deficiency and insufficiency were found in 38.4% and 21.9% of 
the participants, respectively [9]. The measurement of Vitamin D is 
costly in Indonesia. The data about the prevalence of Vitamin D and 
its determinant factors are very limited. This study can be a basis 
of adequate management of diabetes and diabetic neuropathy in 
Indonesia. This study aims to measure the prevalence of Vitamin D 




The research was conducted in Bethesda Hospital Yogyakarta, 
Indonesia. The research was carried out during the period from 
October 2019 to December 2019. This study is a cross-sectional study 
in patients with T2DM that suffers from PDN. The data were obtained 
from 53 study subjects with PDN. The study included all patients 
above the age of 18 years with symptoms suggestive of peripheral 
neuropathy.
Ethical committee approval
Ethical clearance certificate was obtained from Duta Wacana Christian 
University, Yogyakarta, Indonesia, as the Institutional Ethics Clearance 
Committee (Ethical Approval: 1125/C.16/FK/2019).
After obtaining approval from the Institutional Ethical Committee, 
patients were recruited in the study based on the inclusion criteria. 
Informed consent was obtained and the patients were subjected to 
history and physical examination.
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Study participants: Inclusion criteria and Exclusion criteria
Patients with neuropathy due to causes other than diabetes and those 
who refused informed consent were excluded from the study.
Inclusion criteria
The following criteria were included in the study:
•	 Male and female
•	 18 years old
•	 Diagnosed as PDN based on diabetic neuropathy examination (DNE) 
and diabetic neuropathy symptom (DNS) examination
•	 Low Vitamin D status.
Exclusion criteria
The following criteria were excluded from the study:
•	 Subjects with significant renal and liver problem
•	 Subjects with known hypersensitivity with Vitamin D
•	 Pregnancy and breastfeeding patients
•	 Patients that enrolled any clinical trial within a month.
Sampling technique and sample size estimation
The sampling technique was obtained by consecutive sampling method. 
The sample size was calculated based on an estimate of 80% prevalence 
of low Vitamin D in diabetic neuropathy patients, allowing for an error 
of 10%, from total 350 diabetic patients in 1 year from medical record 
data, and thereby, a total of 53 patients were recruited.
Data collection
The diagnosis of diabetic peripheral neuropathy based on systematic 
measurement by neurologist with DNS and DNE tools. T2DM patients 
were obtained from the outpatient neurology clinic of Bethesda 
Hospital Yogyakarta, Indonesia. A pre-designed questionnaire was 
used to collect data on patient’s age, gender, duration since diagnosis of 
diabetes, other comorbidities, drug history, any diabetic complications, 
and current treatment for diabetes. The severity of neuropathy was 
measured with the Toronto Clinical Neuropathy Scoring (TCNS) system. 
The individual patient’s TCNS was documented out of a total of 19. 
The severity of neuropathy was classified based on the score as: No 
neuropathy (0–5), mild neuropathy (6–8), moderate (9–11), and severe 
diabetic neuropathy (12–19).
The Vitamin D levels were measured by a standardized method in 
the Prodia Research laboratory. Measurement of 25(OH)D levels was 
done by enzyme immunoassays for the quantitative measurement 
of total serum 25(OH)D levels. The levels <10 ng/mL are deficiency, 
10–29 ng/mL are in-sufficiency, and 30–100 ng/mL are sufficiency. We 
also performed a systematic search in PubMed for other similar studies 
worldwide for data comparison.
Data analysis
Continuous variables were assessed for normality using Kolmogorov–
Smirnov’s test. If the variables were normally distributed, they 
were expressed as mean±standard deviation, otherwise mean 
rank. Categorical variables were expressed either as percentages or 
proportions. Comparison of normally distributed continuous variables 
was done by independent sample t-test, non-normally distributed 
continuous variables by the Mann–Whitney U-test, and significant 
variable continuous by multivariate linear regression. Data analysis 
and validation were carried out by SPSS Statistics version 23. All p<0.05 
were considered statistically significant.
RESULTS AND DISCUSSION
This study was conducted on 53 subjects of PDN with a much higher 
proportion of 42 females (79.2%) and 11 males (20.8%) had statistically 
significant relationships with Vitamin D levels (p=0.028). The average 
age of PDN patients in this study was 57.83±8.79 years. The results of 
this study are almost the same as the previous studies which showed 
that the number of females (57.9%) was significantly greater (p=0.001) 
than male (42.1%) with an average age of 57.83±8.79 [9]. The duration 
of patients suffering from diabetes is mostly <10 years and only a 
few have poor glycemic control. Based on age, diabetes duration, and 
differences in clinical neuropathy, females had a greater prevalence 
of occurrence neuropathy and 50% increased risk severe neuropathy 
symptoms than males [10].
The high prevalence of the occurrence of Vitamin D deficiency has been 
reported worldwide. Vitamin D deficiency plays an important role in the 
process of the occurrence of non-bone diseases, such as diabetes and 
cardiovascular disease [11]. The average of Vitamin D levels in this study 
was 15.57±6.99 ng/mL. Table 1 shows that the prevalence of low Vitamin 
D levels in the Indonesian population was 98.11%. Only one study subject 
has sufficient Vitamin D levels. The proportion of subjects with deficiency 
is significant 12/53 (22.6%). Most of the study subjects have insufficient 
Vitamin D levels as many as 75.5% and 22.6% had Vitamin D deficiency. 
These results are similar to previous studies in Greeks, with 17.5% 
having Vitamin D deficiency and 63.3% with Vitamin D insufficiency [12]. 
The previous studies on Asians in the UK found 13% and 70% of type 2 
diabetics had Vitamin D deficiency and insufficiency, respectively [13]. 
This result is consistent with some previous studies (Table 2).
The results of evaluations of 9773 US adults over the age of 18 carried 
out by the National Health and Nutrition Examination (NHANES) group 
study (2003–2006), confirmed a mechanistic relationship between 
serum Vitamin D levels, glucose homeostasis, and the evolution of 
diabetes mellitus. The National Health and Nutrition Examination 
Survey (NHANES) III study (1988 and 1994) demonstrated that there 
is a strong inverse association between low levels of Vitamin D and the 
prevalence of diabetes [19].
Table 1: Characteristics and clinical features of the study 
subjects





<60 years old 33 62.2
≥60 years old 20 37.8























No neuropathy (0–5) 0 0
Mild neuropathy (6–8) 11 20.8
Moderate (9–11) 19 35.8
Severe (12–19) 23 43.4
Vitamin D levels (ng/mL)
Deficiency <10 12 22.6
Insufficiency 10–29 40 75.5
Sufficiency 30–100 1 1.9
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Vitamin D is produced in the skin by being exposed to direct sunlight. 
Vitamin D is an essential fat-soluble precursor steroid in the human 
body. Cholecalciferol (D3) and ergocalciferol (D2) are the most important 
forms of Vitamin D. The human body cannot produce D2 but it can be 
digested in fortified foods or supplements [20]. The lower prevalence 
of Vitamin D deficiency in various populations can be caused due to 
climate factors. Tropical countries get greater sun exposure and also 
longer than European countries some Asian and American countries [9]. 
Multiple factors contribute to this finding, which include sun exposure, 
atmospheric pollution, the degree of physical activity, clothing, cultural, 
and dietary habits [21].
Vitamin D deficiency contributes significantly to the pathogenesis of 
the two types of diabetes by directly acts on insulin producing cells 
(β cells) in the pancreas to produce more insulin and increasing insulin 
resistance [22]. In a previous study, there was evidence that Vitamin D 
plays a role in the process of regulating beta-cell function by influencing 
insulin secretion, inhibiting beta-cell apoptosis, or by increasing beta-
cell [23]. In this study, the prevalence of low Vitamin D levels mostly 
occurred in PDN patients suffering from T2DM. T2DM is a disease 
caused by abnormalities in insulin sensitivity and the process of insulin 
secretion. This disorder is usually associated with a sedentary lifestyle 
and higher levels of inflammation cytokines [24]. Based on previous 
research, it is suggested that Vitamin D can play a role in increasing the 
function of beta-cells and increasing insulin sensitivity. NHANES study 
shows an inverse correlation between 25(OH)D and the incidence of 
T2DM/insulin resistance [25].
Diabetic patients tend to be easily deficient in B vitamins, Vitamin C, 
Vitamin D, and many micronutrients, such as chromium, zinc, selenium, 
magnesium, iron, and manganese. A study by Ahmadieh et al. explains 
that low concentrations of 25(OH)D are independent risk factors for 
PDN. Studies conducted in patients with T2DM have been confirmed 
that Vitamin D deficiency is associated with neuropathy [7]. Nerve 
growth factor (NGF) is known to have neuronal benefits in cases of 
diabetic peripheral neuropathy. Previous confirms that Vitamin D3 
(tacalcitol) has been shown to increase expression from NGF [26]. 
In patients with Vitamin D deficiency, there was proven of increased 
NGF production after correction with Vitamin D supplementation. 
Therefore, Vitamin D3 may be useful in preventing and treating 
neurotropic deficits [27].
In this study, the results of the normality test are not significant. 
Therefore, a Mann–Whitney statistical test was performed, which 
demonstrated in Table 3 regarding the determinant factor low Vitamin 
D levels in patients with PDN or to assessing the Vitamin D levels 
comparison based on the characteristic data. Based on statistical tests, 
there were no significant differences in the variables of age, duration of 
diabetes, cardiovascular disease, antidiabetic drugs, and insulin. There 
were only three variables with significant results: Gender, hypertension, 
and controlled complications. To confirm that three variables are 
related as determinant factors that influence Vitamin D levels, we do a 
multivariate linear regression test.
Based on multivariate linear regression analysis, all the variables had 
a significant result that presents in Table 4. These results indicate that 
there was a relationship between gender, controlled complications, and 
hypertension with Vitamin D levels.
The previous studies showed that Vitamin D deficiency was associated 
with significant coronary artery stenosis in a community-based 
elderly cohort [28]. Another study showed that low Vitamin D levels 
are associated with an increased risk of various diseases, such as 
cancer, hypertension, cardiovascular disease, and another metabolic 
disease [29]. In this study, there was a significant relationship between 
low levels of Vitamin D and hypertension (p=0.027). This results 
similar to the previous study, there were significant results between 
hypertension and Vitamin D levels (p=0.003) [11]. The current study 
suggests, there was a relationship between hypertension with Vitamin 
D levels. Park et al. also found a significant inverse relationship with 
serum Vitamin D levels and systolic and diastolic blood pressures [30].
The previous study confirms the findings, there was an association 
between Vitamin D deficiency and hypertension as cardiovascular 
risk factors. Vitamin D3 and its analogs play a role in inhibiting renin 
secretion and activity, thus acting as a negative endocrine regulator of 
the renin-angiotensin system [31]. In addition, Vitamin D3 has a direct 
effect on blood vessel walls, which will have antiproliferative effects 
Table 2: Prevalence of Vitamin D deficiency reported in the 
previous studies among diabetic patients






Palazhy et al., 2016 [8] Indians 71.4 15
Kostoglou-Athanassiou 
et al., 2013 [12]
Greeks 17.5 63.3
Lee et al., 2012 [14] Koreans 89 8
Zahrani et al., 2013 [15] Saudi 59.8 38.6
Bayani et al., 2014 [16] Iranians 64.2 25
He et al., 2017 [17] Chinese 80 14.4
Karau et al., 2019 [9] Kenyans 38.4 21.9
Khan et al., 2019 [18] Pakistan 43.2 36.5
Table 3: The Vitamin D levels comparison based on the 
determinant factors







<60 years old 25.44 0.344
≥60 years old 29.58




















Table 4: Multivariate linear regression model for Vitamin D 
levels comparison based on the significant determinant factors
Variables p-value Standardized β 95.0% confidence 
interval




Hypertension 0.027* 0.270 0.442–7.057
*Significance when p<0.05
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on vascular smooth muscle cells. In vitro studies of vascular smooth 
muscle cells revealed several mechanisms by which 1,25-(OH)2D3 
might contribute to pathogenesis occurrence of vascular lesions due 
to dose-dependent Vitamin D3 activating p38 which is activated by 
mitogen protein kinase and phosphatidylinositol kinase [32].
NHAES previous study confirmed that insulin resistance, renal function, 
and Vitamin D status of 14,679 patients assessed, and Vitamin D 
deficiency had been reported associated with a high risk of developing 
macrovascular and microvascular complications in patients with type 
1 as and type 2 diabetes [33]. Relationship between serum 25-OH 
concentration of Vitamin D on incidence macrovascular (including 
myocardial infarction and stroke) and microvascular (retinopathy, 
nephropathy, neuropathy, and amputation) analyzed showed that 
a difference of 50 nmol/L in blood concentrations of 25(OH)D was 
associated with a 23% change (p=0.007) in risk of macrovascular 
complications during the study [34].
In this study, we found that most PDN patients have controlled 
complications. Complications in PDN patients are also significantly 
associated with Vitamin D levels (p=0.005). This result similar to 
the past study showed that there is a definite correlation between 
Vitamin D levels and diabetes and poorly controlled diabetics. Poorly 
controlled diabetics have further lower values of Vitamin D when 
compared with patients with good glycemic control. It is known that 
poorly controlled diabetic patients are more prone to complications, 
this is because Vitamin D supplementation in diabetics might improve 
glycemic control and quality of life and can reduce morbidity and 
mortality [35].
The limitation of this study is, our study cannot show the causal 
association between glycemic control and Vitamin D levels. It is a 
hospital-based study and hence the results may not be generalized 
to the population on a community basis. The authors could not find 
sufficient subjects with normal Vitamin D status. We also do not 
compare the Vitamin D levels in patients without neuropathy. Further 
studies and clinical trials are warranted.
CONCLUSION
All patients with PDN in this study had a high prevalence of Vitamin D 
deficiency. This high prevalence of Vitamin D deficiency also has been 
reported worldwide. Physician should be aware and continue to treat 
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